In the short-term, the firm is looking to enter markets close to home—including Taiwan, Macau, Singapore, Hong Kong and Saudi ...

A personalised Merck-Moderna vaccine improved melanoma outcomes when paired with Keytruda. The Phase 3 findings broaden the ...

Provided by On Hospital [Financial News] Pancreatic cancer, known as the “silent cancer,” has one of the lowest five-year ...

Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated ...

Single agent lorigerlimab demonstrated encouraging preliminary clinical activity in clear cell gynecologic cancer (CCGC) with a confirmed ORR of ...

Detailed price information for Theralase Technologies Inc. (TLT-X) from The Globe and Mail including charting and trades.

The Second International Congress on Childhood Oncology was recently held in Samarkand as part of the World Summit on ...

Vancouver's James Howard is paying $90,000 a month for a new pancreatic cancer treatment that may add a few more months to his life. But, he's far from the only Canadian who is faced with having to ...

Discover how the new personalized cancer vaccine intismeran combined with Keytruda lowers melanoma relapse risk, achieving an 82% 2-year survival rate.

Trade-margin caps on cancer drugs may reduce prices for patients but risk shifting costs to hospitals, supply chains, and ...

A new personalised cancer treatment could offer hope to people at high risk of melanoma returning after surgery, following ...